The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.

David F. McDermott

Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Novartis; Pfizer

Research Funding - Prometheus

Jeffrey R. Infante

Consultant or Advisory Role - GlaxoSmithKline (U)

Martin Henner Voss

Consultant or Advisory Role - Bayer

Honoraria - Novartis

Research Funding - Bristol-Myers Squibb; Pfizer

Robert J. Motzer

Consultant or Advisory Role - Genentech; Merck; Pfizer

Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer

Expert Testimony - Pfizer

John B. A. G. Haanen

Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Roche

Research Funding - GlaxoSmithKline

Simon Chowdhury

Consultant or Advisory Role - GlaxoSmithKline

Honoraria - GlaxoSmithKline

Rodolfo F. Perini

Employment or Leadership Position - Merck

Robert Iannone

Employment or Leadership Position - Merck

Stock Ownership - Merck

Rachel Hodge